Citations

Clear

9383 citation(s) found for "Thomas, PS".

Production and Characterization of Monoclonal Antibodies to Human Sclerostin
Craig, Theodore A., Sommer, Stacy, Beito, Thomas G., Kumar, Rajiv , Kumar, Rajiv

Mayo Clinic

Hybridoma | October 26, 2009 | Volume: 28 | Issue: 5 | Pages: 377-381

10.1089/hyb.2009.0036 | PMID 19857121 Get It

We developed and characterized monoclonal antibodies directed against the amino-terminal and carboxy-terminal regions of human and mouse sclerostin (scl). Amino-terminal and carboxy-terminal scl peptides with limited homology to scl domain-containing protein-1 were synthesized using f-moc chemistry. The peptides were conjugated to keyhole limpet hemocyanin and the conjugates were used for immunization of mice. Monoclonal antibodies were obtained and characterized using bacterially expressed and insect cell–expressed recombinant scl. The amino-terminal (IgG 2aK) and carboxy-terminal (IgG 2bK) antibodies bound bioactive sclerostin that was expressed in an insect-cell expression system with dissociation constants in the nanomolar range. The antibodies are potentially useful agents that can be used for modulating sclerostin bioactivity.
An NSAID-like Compound, FT-9, Preferentially Inhibits γ-Secretase Cleavage of the Amyloid Precursor Protein Compared to Its Effect on Amyloid Precursor-like Protein 1
Frigerio, Carlo Sala , Kukar, Thomas , Fauq, Abdul H. , Engel, Paul C., Golde, Todd E. , Walsh, Dominic M.

Mayo Clinic

Biochemistry | October 12, 2009 | Volume: 48 | Issue: 46 | Pages: 10894-10904

10.1021/bi901237k | PMID 19821615 Get It

Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin Lymphoma
Ansell, Stephen M. , Hurvitz, Sara A. , Koenig, Patricia, LaPlant, Betsy, Kabat, Brian, Fernando, Donna, Inwards, David J. , Verma, Meena, Erlichman, Charles , Lowy, Israel , Timmerman, John M. , Habermann, Thomas M. , Yamada, Reiko E.

Mayo Clinic

Clinical Cancer Research | October 6, 2009 | Volume: 15 | Issue: 20 | Pages: 6446-6453

10.1158/1078-0432.ccr-09-1339 | PMID 19808874 Get It

Abstract Purpose: The growth of non–Hodgkin lymphomas can be influenced by tumor–immune system interactions. Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a negative regulator of T-cell activation that serves to dampen antitumor immune responses. Blocking anti–CTLA-4 monoclonal antibodies improves host resistance to immunogenic tumors, and the anti–CTLA-4 antibody ipilimumab (MDX-010) has clinical activity against melanoma, prostate, and ovarian cancers. Experimental Design: We did a phase I trial of ipilimumab in patients with relapsed/refractory B-cell lymphoma to evaluate safety, immunologic activity, and potential clinical efficacy. Treatment consisted of ipilimumab at 3 mg/kg and then monthly at 1 mg/kg × 3 months (dose level 1), with subsequent escalation to 3 mg/kg monthly × 4 months (dose level 2). Results: Eighteen patients were treated, 12 at the lower dose level and 6 at the higher dose level. Ipilimumab was generally well tolerated, with common adverse events attributed to it, including diarrhea, headache, abdominal pain, anorexia, fatigue, neutropenia, and thrombocytopenia. Two patients had clinical responses; one patient with diffuse large B-cell lymphoma had an ongoing complete response (>31 months), and one with follicular lymphoma had a partial response lasting 19 months. In 5 of 16 cases tested (31%), T-cell proliferation to recall antigens was significantly increased (>2-fold) after ipilimumab therapy. Conclusions: Blockade of CTLA-4 signaling with the use of ipilimumab is well tolerated at the doses used and has antitumor activity in patients with B-cell lymphoma. Further evaluation of ipilimumab alone or in combination with other agents in B-cell lymphoma patients is therefore warranted. (Clin Cancer Res 2009;15(20):6446–53)
Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Wiernik, Peter H. , Moore, Timothy D., Reeder, Craig B. , Cole, Craig E. , Justice, Glen R., Voralia, Michael, Pietronigro, Dennis, Takeshita, Kenichi , Ervin‐Haynes, Annette, Zeldis, Jerome B. , Witzig, Thomas E. , Kaplan, Henry G. , Vose, Julie M.

Mayo Clinic

Journal of Clinical Oncology | October 6, 2009 | Volume: 27 | Issue: 32 | Pages: 5404-5409

10.1200/jco.2008.21.1169 | PMID 19805688 Get It

PurposeLenalidomide is a novel immunomodulatory agent with antiproliferative activities. Given its efficacy in a wide range of hematologic malignancies, we conducted a phase II trial (NHL-001) of single-agent lenalidomide in indolent non-Hodgkin's lymphoma (NHL).Patients and MethodsPatients with relapsed/refractory indolent NHL were eligible, with no limit on the number of previous therapies. Oral lenalidomide 25 mg was self-administered once daily on days 1 to 21 of every 28-day cycle for up to 52 weeks as tolerated, or until disease progression. The primary end point was objective response rate (ORR), with secondary end points of duration of response (DR), progression-free survival (PFS), and safety.ResultsForty-three enrolled patients were assessable for response and safety. Patients received a median of three prior systemic therapies (range, 1 to 17) and half were refractory to last therapy. ORR was 23% (10 of 43), including a 7% complete response (CR) or unconfirmed CR rate. Twenty-seven percent (six of 22) of patients with follicular lymphoma grade 1 or 2, and 22% (four of 18) with small lymphocytic lymphoma responded to therapy. Median DR was not reached, but was longer than 16.5 months with seven of 10 responses ongoing at 15 to 28 months. Median PFS for the whole group was 4.4 months (95% CI, 2.5 to 10.4 months). Adverse events were predictable and manageable; the most common grade 3 or 4 adverse events were neutropenia (30% and 16%, respectively) and thrombocytopenia (14% and 5%, respectively).ConclusionOral lenalidomide monotherapy produces durable responses with manageable adverse events in patients with relapsed/refractory indolent NHL, warranting further investigation of treatment for indolent NHL.
Surface Plasmon Resonance Binding Kinetics of Alzheimer’s Disease Amyloid β Peptide-Capturing and Plaque-Binding Monoclonal Antibodies
Ramakrishnan, Muthu, Kandimalla, Karunya K. , Wengenack, Thomas M., Howell, Kyle G., Poduslo, Joseph F., Kandimalla, Karunya K

Mayo Clinic

Biochemistry | September 23, 2009 | Volume: 48 | Issue: 43 | Pages: 10405-10415

10.1021/bi900523q | PMID 19775170 Get It

Rearrangements and Amplification of IER3 ( IEX-1 ) Represent a Novel and Recurrent Molecular Abnormality in Myelodysplastic Syndromes
Steensma, David P. , Neiger, Jessemy D., Porcher, Julie C., Keats, Jonathan J. , Bergsagel, P. Leif , Dennis, Thomas R., Knudson, Ryan A., Jenkins, Robert B. , Santana-Dávila, Rafael , Kumar, Rajiv , Ketterling, Rhett P. , Bergsagel, P. Leif , Kumar, Rajiv , Ketterling, Rhett P , Keats, Jonathan J , Steensma, David P

Mayo Clinic

Cancer Research | September 22, 2009 | Volume: 69 | Issue: 19 | Pages: 7518-7523

10.1158/0008-5472.can-09-1428 | PMID 19773435 Get It

Abstract IER3 (formerly IEX-1) encodes a 27-kDa glycoprotein that regulates death receptor–induced apoptosis, interacts with NF-κB pathways, and increases expression rapidly in response to cellular stresses such as irradiation. Animal models, gene expression microarray experiments, and functional studies in cell lines have suggested a potential role for IER3 in oncogenesis, but, to date, no abnormalities of IER3 at the DNA level have been reported in patients with neoplasia. Here, we describe breakpoint cloning of a t(6;9)(p21;q34) translocation from a patient with a myelodysplastic syndrome (MDS), facilitated by conversion technology and array-based comparative genomic hybridization, which revealed a rearrangement translocating the IER3 coding region away from critical flanking/regulatory elements and to a transcript-poor chromosomal region, markedly decreasing expression. Using split-signal and locus-specific fluorescence in situ hybridization (FISH) probes, we analyzed 204 patients with diverse hematological malignancies accompanied by clonal chromosome 6p21 abnormalities, and found 8 additional patients with MDS with IER3 rearrangements (translocations or amplification). Although FISH studies on 157 additional samples from patients with MDS and a normal-karyotype were unrevealing, and sequencing the IER3 coding and proximal promoter regions of 74 MDS patients disclosed no point mutations, reverse transcription-PCR results suggested that dysregulated expression of IER3 is common in MDS (61% >4-fold increase or decrease in expression with decreased expression primarily in early MDS and increased expression primarily in later MDS progressing toward leukemia), consistent with findings in previous microarray experiments. These data support involvement of IER3 in the pathobiology of MDS. [Cancer Res 2009;69(19):7518–23]
Retinal microvascular abnormalities and cognitive decline
Lesage, Suzanne , Wong, Tien Yin , Szklo, Moysés , Catellier, Diane , Cole, Stephen R. , Coker, Laura H., Sharrett, A. Richey, Mosley, Thomas H. , Knopman, David S. , Klein, Ronald , Coresh, Josef , Wong, Tien Y

Mayo Clinic

Neurology | September 14, 2009 | Volume: 73 | Issue: 11 | Pages: 862-868

10.1212/wnl.0b013e3181b78436 | PMID 19752453 Get It

MicroRNA Expression Signatures in Barrett's Esophagus and Esophageal Adenocarcinoma
Yang, Hushan , Gu, Jian , Wang, Kenneth K. , Zhang, Wei , Xing, Jinliang , Wu, Xifeng , Chen, Zhi‐Nan , Ajani, Jaffer A. , Gu, Jian

Mayo Clinic

Clinical Cancer Research | September 8, 2009 | Volume: 15 | Issue: 18 | Pages: 5744-5752

10.1158/1078-0432.ccr-09-0385 | PMID 19737949 Get It

Abstract Purpose: Esophageal adenocarcinoma is a highly aggressive malignancy that frequently develops from Barrett's esophagus, a premalignant pathologic change occurring in the lower end of the esophagus. Identifying Barrett's esophagus patients at high risk of malignant transformation is essential to the prevention of esophageal adenocarcinoma. Although microRNA (miRNA) expression signatures have been associated with the etiology and prognosis of several types of cancers, their roles in the development of esophageal adenocarcinoma have not been extensively evaluated. Experimental Design: In this study, we analyzed the expression patterns of 470 human miRNAs using Agilent miRNA microarray in 32 disease/normal-paired tissues from 16 patients diagnosed with Barrett's esophagus of either low- or high-grade dysplasia, or esophageal adenocarcinoma. Results: Using unsupervised hierarchical clustering and class comparison analyses, we found that miRNA expression profiles in tissues of Barrett's esophagus with high-grade dysplasia were significantly different from their corresponding normal tissues. Similar findings were observed for esophageal adenocarcinoma, but not for Barrett's esophagus with low-grade dysplasia. The expression patterns of selected miRNAs were further validated using quantitative reverse transcription real-time PCR in an independent set of 75 pairs of disease/normal tissues. Finally, we identified several miRNAs that were involved in the progressions from low grade-dysplasia Barrett's esophagus to esophageal adenocarcinoma. Conclusions: We showed that miRNAs were involved in the development and progression of esophageal adenocarcinoma. The identified significant miRNAs that may become potential targets for early detection, chemoprevention, and treatment of esophageal cancer. (Clin Cancer Res 2009;15(18):5744–52)
Candidate Gene Polymorphisms for Ischemic Stroke
Matarín, Mar, Brown, W. Mark , Dena, Hernandez, Britton, Angela, Vrieze, Fabienne Wavrant De, Brott, Thomas G. , Brown, Robert D., Worrall, Bradford B. , Case, L. Douglas, Metter, E. Jeffrey , Gamble, Dale M., Hardy, John , Rich, Stephen S. , Singleton, Andrew , Chanock, Stephen Jacob , Ferrucci, Luigi , Meschia, James F. , Rich, Stephen S , Hardy, John

Mayo Clinic

Stroke | September 4, 2009 | Volume: 40 | Issue: 11 | Pages: 3436-3442

10.1161/strokeaha.109.558015 | PMID 19729601 Get It

Background and Purpose— Ischemic stroke (IS) is a multifactorial disorder with strong evidence from twin, family, and animal model studies suggesting a genetic influence on risk and prognosis. Several candidate genes for IS have been proposed, but few have been replicated. We investigated the contribution of 67 candidate genes (369 single nucleotide polymorphisms [SNPs]) on the risk of IS in a North American population of European descent. Methods— Two independent studies were performed. In the first, 342 SNPs from 52 candidate genes were genotyped in 307 IS cases and 324 control subjects. The SNPs significantly associated with IS were tested for replication in another cohort of 583 IS cases and 270 control subjects. In the second study, 212 SNPs from 62 candidate genes were analyzed in 710 IS cases with subtyping available and 3751 control subjects. Results— None of the candidate genes (SNPs) were significantly associated with IS risk independent of known stroke risk factors after correction for multiple hypotheses testing. Conclusion— These results are consistent with previous meta-analyses that demonstrate an absence of genetic association of variants in plausible candidate genes with IS risk. Our study suggests that the effect of the investigated SNPs may be weak or restricted to specific populations or IS subtypes.
Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for P
Micallef, Ivana N. , Stiff, Patrick J. , Bolwell, Brian J., Jacobsen, Eric D. , Nademanee, Auayporn, McCarty, John M. , Bridger, Gary, Calandra, Gary, DiPersio, John F. , Maziarz, Richard Thomas

Mayo Clinic

Journal of Clinical Oncology | August 31, 2009 | Volume: 27 | Issue: 28 | Pages: 4767-4773

10.1200/jco.2008.20.7209 | PMID 19720922 Get It

Purpose This study evaluates the safety and efficacy of plerixafor (AMD3100), a CXCR4 antagonist, in mobilizing hematopoietic stem cells for autologous stem-cell transplantation in non-Hodgkin's lymphoma (NHL) patients. Patients and Methods This is a phase III, multicenter, randomized (1:1), double-blind, placebo-controlled study. Patients with non-Hodgkin's lymphoma requiring an autologous hematopoietic stem-cell transplantation in first or second complete or partial remission were eligible. Patients received granulocyte colony-stimulating factor (G-CSF; 10 μg/kg) subcutaneously daily for up to 8 days. Beginning on evening of day 4 and continuing daily for up to 4 days, patients received either plerixafor (240 μg/kg) or placebo subcutaneously. Starting on day 5, patients began daily apheresis for up to 4 days or until ≥ 5 × 10 6 CD34+ cells/kg were collected. The primary end point was the percentage of patients who collected ≥ 5 × 10 6 CD34+ cells/kg in 4 or fewer apheresis days. Results This report presents all data for all patients (n = 298) through 12 months follow-up. Eighty-nine (59%) of 150 patients in the plerixafor group and 29 (20%) of 148 patients in the placebo group met the primary end point (P < .001). One hundred thirty-five patients (90%) in plerixafor group and 82 patients (55%) in placebo group underwent transplantation after initial mobilization. Median time to engraftment was similar in both groups. The most common plerixafor-associated adverse events were GI disorders and injection site reactions. Conclusion Plerixafor and G-CSF were well tolerated and resulted in a significantly higher proportion of patients with non-Hodgkin's lymphoma achieving the optimal CD34+ cell target for transplantation in fewer apheresis days, compared with G-CSF alone.